| [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia -> Monitor Keywords |
|
|
 
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophreniaRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai, Hetero Ring Is Six-membered And Includes At Least Nitrogen And Oxygen As Ring Hetero Atoms (e.g., Monocyclic 1,2- And 1,3-oxazines, Etc.), Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos (e.g., Maytansinoids, Etc.), Bicyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos (e.g., 1,4-benzoxazines, Etc.)[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060287310, [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia. Brief Patent Description - Full Patent Description - Patent Application Claims
BACKGROUND OF THE INVENTION [0001] This invention relates to [1,8]naphthyridin-2-ones and related compounds, methods of making such compounds, pharmaceutical compositions containing them, and their use for the treatment of schizophrenia and other central nervous system (CNS). [0002] The [1,8]naphthyridin-2-ones and related compounds of this invention bind to dopamine D.sub.2 receptors. Some exhibit activity as partial agonists of D.sub.2 receptors, while others exhibit activity as antagonists of such receptors. [0003] Other heterocyclic derivatives that are useful for the treatment of schizophrenia are referred to in U.S. Pat. No. 5,350,747, which issued on Sep. 27, 1994, and in U.S. Pat. No. 6,127,357, which issued on Oct. 3, 2000. These patents are incorporated herein by reference in their entireties. [0004] Other heterocyclic derivatives that have been stated to be useful as antipsychotic agents are those referred to in PCT patent publication WO 93/04684, which published on Mar. 18, 1993, and European patent application EP 402644A, which was published on Dec. 19, 1990. These patent applications are incorporated herein by reference in their entireties. SUMMARY OF THE INVENTION [0005] The present invention relates to compounds of the formula 1 [0006] A is --(CH.sub.2).sub.mCH.sub.2--, --(CH.sub.2).sub.mO--, or --(CH.sub.2).sub.mNH--, wherein m is an integer from 2 to 5 and wherein one or two of the carbon or nitrogen atoms of --(CH.sub.2).sub.mCH.sub.2--, --(CH.sub.2).sub.mO-- and --(CH.sub.2).sub.mNH-- can be substituted, optionally and independently, with one or two substituents that are selected, independently, from fluoro and methyl, or with two substituents attached to the same carbon atom that form, together with the carbon to which they are attached, a spirocyclopropyl or spirocyclobutyl ring; [0007] D is N, C, or CH, provided that when D is N each carbon atom covalently attached to D is attached through a single bond; [0008] Z and Q are independently N, C, or CH, provided that at least one of Z and Q is N; [0009] --XY-- is --CH.sub.2--CH.sub.2--, --CH.dbd.CH--, --CH.sub.2--NH--, --NH--CH.sub.2--, --N.dbd.CH--, --CH.dbd.N--, --O--CH.sub.2--, or --CH.sub.2--O--, wherein --XY-- can optionally be substituted, at any available bonding site, by one to four substituents R.sup.2, R.sup.2', R.sup.3 and R.sup.3'; [0010] V and W are independently N, C, or CH; [0011] ring AA is a saturated or unsaturated 5- 6- or 7-membered carbocyclic ring wherein one, two or three of the carbon atoms of ring AA that are not shared with the benzo ring of group (ii) can be replaced, optionally and independently, by a nitrogen, oxygen or sulfur atom; [0012] R.sup.1 is hydrogen, --C(.dbd.O)CH.sub.3, or (C.sub.1-C.sub.3)alkyl; [0013] R.sup.2, R.sup.2', R.sup.3 and R.sup.3' are independently selected from hydrogen, halo, cyano, oxo, hydroxy, --C(.dbd.O)CH.sub.3, (C.sub.1-C.sub.4)alkyl, and (C.sub.1-C.sub.4)alkoxy, wherein the alkyl moieties of the (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, and --C(.dbd.O)CH.sub.3 groups can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent; [0014] R.sup.4 and R.sup.5 are independently selected from hydrogen, halo, cyano, hydroxy, --C(.dbd.O)CH.sub.3, (C.sub.1-C.sub.4)alkyl, and (C.sub.1-C.sub.4)alkoxy, wherein the alkyl moieties of the (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, and --C(.dbd.O)CH.sub.3 groups can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent; [0015] R.sup.6 and R.sup.7 are selected, independently, from hydrogen and methyl; [0016] R.sup.8, R.sup.9, R.sup.10, R.sup.11, and R.sup.12 are independently selected from hydrogen, halo, --C(.dbd.O)CH.sub.3, (C.sub.1-C.sub.4)alkyl, and (C.sub.1-C.sub.4)alkoxy, aryl, and aryloxy, wherein the alkyl moieties of the (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, and --C(.dbd.O)CH.sub.3 groups and the aryl and aryloxy moieties can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent; [0017] R.sup.13 and R.sup.14 are independently selected from hydrogen, halo, cyano, oxo, hydroxy, --C(.dbd.O)CH.sub.3, (C.sub.1-C.sub.4)alky, and (C.sub.1-C.sub.4)alkoxy, wherein the alkyl moieties of the (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy, and --C(.dbd.O)CH.sub.3 groups can be optionally substituted with from one to three fluoro atoms and can also be optionally substituted with an amino or hydroxy substituent; [0018] and the pharmaceutically acceptable salts of such compounds. [0019] This invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [0020] The compounds of formula 1 have useful pharmaceutical and medicinal properties. [0021] This invention also relates to a method of treating a disorder or condition selected from the group consisting of single episodic or recurrent major depressive disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression including anorexia, weight loss, insomnia, early morning waking or psychomotor retardation; atypical depression (or reactive depression) including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression; bipolar disorders or manic depression, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; conduct disorder; disruptive behavior disorder; attention deficit hyperactivity disorder (ADHD); behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; anxiety disorders such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, for example, specific animal phobias, social anxiety, social phobia, obsessive-compulsive disorder, stress disorders including post-traumatic stress disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophreniform disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinations, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder; mood disorders associated with schizophrenia; delirium, dementia, and amnestic and other cognitive or neurodegenerative disorders, such as Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease, senile dementia, dementia of the Alzheimer's type, memory disorders, loss of executive function, vascular dementia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, or due to multiple etiologies; movement disorders such as akinesias, dyskinesias, including familial paroxysmal dyskinesias, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome; extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced Parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremor; chemical dependencies and addictions (e.g., dependencies on, or addictions to, alcohol, heroin, cocaine, benzodiazepines, nicotine, or phenobarbitol) and behavioral addictions such as an addiction to gambling; and ocular disorders such as glaucoma and ischemic retinopathy in a mammal, including a human, comprising administering to a mammal in need of such treatment an amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition. [0022] This invention also relates to a pharmaceutical composition for treating any disorder or condition listed immediately above, the pharmaceutical composition comprising an amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier. Continue reading about [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia... Full patent description for [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia or other areas of interest. ### Previous Patent Application: [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia Next Patent Application: Isoquinoline compounds and methods of use thereof Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia patent info. IP-related news and info Results in 0.79155 seconds Other interesting Feshpatents.com categories: Computers: Graphics , I/O , Processors , Dyn. Storage , Static Storage , Printers 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
